SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hamilton Alan)
 

Sökning: WFRF:(Hamilton Alan) > (2020-2024) > Plasma biomarkers o...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003709naa a2200469 4500
001oai:gup.ub.gu.se/334958
003SwePub
008240528s2023 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/3349582 URI
0247 a https://doi.org/10.1017/S00332917230019522 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Hamilton, Calum Alexander4 aut
2451 0a Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies
264 1c 2023
520 a Background. Blood biomarkers of Alzheimer's disease (AD) may allow for the early detection of AD pathology in mild cognitive impairment (MCI) due to AD (MCI-AD) and as a co-pathology in MCI with Lewy bodies (MCI-LB). However not all cases of MCI-LB will feature AD pathology. Disease-general biomarkers of neurodegeneration, such as glial fibrillary acidic protein (GFAP) or neurofilament light (NfL), may therefore provide a useful supplement to AD biomarkers. We aimed to compare the relative utility of plasma A beta 42/40, p-tau181, GFAP and NfL in differentiating MCI-AD and MCI-LB from cognitively healthy older adults, and from one another.Methods. Plasma samples were analysed for 172 participants (31 healthy controls, 48 MCI-AD, 28 possible MCI-LB and 65 probable MCI-LB) at baseline, and a subset (n = 55) who provided repeated samples after >= 1 year. Samples were analysed with a Simoa 4-plex assay for A beta 42, A beta 40, GFAP and NfL, and incorporated previously-collected p-tau181 from this same cohort.Results. Probable MCI-LB had elevated GFAP (p < 0.001) and NfL (p = 0.012) relative to controls, but not significantly lower A beta 42/40 (p = 0.06). GFAP and p-tau181 were higher in MCI-AD than MCI-LB. GFAP discriminated all MCI subgroups, from controls (AUC of 0.75), but no plasma-based marker effectively differentiated MCI-AD from MCI-LB. NfL correlated with disease severity and increased with MCI progression over time (p = 0.011).Conclusion. Markers of AD and astrocytosis/neurodegeneration are elevated in MCI-LB. GFAP offered similar utility to p-tau181 in distinguishing MCI overall, and its subgroups, from healthy controls.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
653 a Alzheimer's disease
653 a dementia with Lewy bodies
653 a mild cognitive impairment
653 a neurodegeneration
653 a plasma biomarkers
7001 a O'Brien, John4 aut
7001 a Heslegrave, Amanda4 aut
7001 a Laban, Rhiannon4 aut
7001 a Donaghy, Paul4 aut
7001 a Durcan, Rory4 aut
7001 a Lawley, Sarah4 aut
7001 a Barnett, Nicola4 aut
7001 a Roberts, Gemma4 aut
7001 a Firbank, Michael4 aut
7001 a Taylor, John-Paul4 aut
7001 a Zetterberg, Henrik,d 1973u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xzethe
7001 a Thomas, Alan4 aut
7102 a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org
7730 t PSYCHOLOGICAL MEDICINEg 53:16, s. 7865-7873q 53:16<7865-7873x 0033-2917x 1469-8978
8564 8u https://gup.ub.gu.se/publication/334958
8564 8u https://doi.org/10.1017/S0033291723001952

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy